Ibiden (4062) Q3 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2025 earnings summary
5 Jun, 2025Executive summary
Net sales for the third quarter ended December 31, 2024, were ¥270,337 million, down 3.5% year-over-year.
Operating profit decreased 5.7% to ¥34,857 million compared to the same period last year.
Profit attributable to owners of parent fell 9.5% to ¥24,801 million year-over-year.
Comprehensive income dropped 56.7% to ¥20,789 million compared to the prior year.
Financial highlights
Gross profit increased to ¥81,971 million, up ¥4,121 million year-over-year.
Basic earnings per share for the quarter were ¥177.56, down from ¥196.13 a year earlier.
Total assets stood at ¥1,105,682 million, a decrease of ¥24,308 million from March 31, 2024.
Capital adequacy ratio improved to 46.1% from 43.8% at the end of the previous fiscal year.
Net cash provided by operating activities was ¥68,182 million, up ¥30,766 million year-over-year.
Outlook and guidance
Full-year net sales forecast is ¥370,000 million, nearly flat year-over-year.
Operating income and ordinary income are both projected at ¥40,000 million, up 15.9% and 21.8% respectively.
Profit attributable to owners of parent is forecast at ¥25,000 million, down 20.6% year-over-year.
Annual dividend forecast remains at ¥40 per share.
Latest events from Ibiden
- Strong Q3 growth, stock split, and major investment plan to boost high-performance IC substrate capacity.4062
Q3 20263 Feb 2026 - Strong sales and profit growth, stock split, and robust outlook driven by electronics.4062
Q2 202631 Oct 2025 - Strong first-quarter growth driven by electronics, with raised full-year outlook.4062
Q1 20261 Aug 2025 - Operating profit rose 38% despite a 7% sales decline, with strong cash flow and stable outlook.4062
Q1 202513 Jun 2025 - Profit growth offset lower sales, but comprehensive income dropped on market-related losses.4062
Q2 202513 Jun 2025 - Profit rose 7% in FY2024, but FY2025 net profit is forecast to decline amid tariff risks.4062
Q4 20256 Jun 2025